George Wilding
Affiliations: | University of Wisconsin, Madison, Madison, WI |
Area:
Toxicology, Oncology, Molecular Biology, Cell BiologyWebsite:
http://faculty.mdanderson.org/George_Wilding/Default.asp?SNID=2Google:
"George Wilding"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Basu H, Wilganowski N, Lieblich J, et al. (2018) Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer Cancer Research. 78 |
| Basu HS, Wilgonowski NL, Lieblich JL, et al. (2018) Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer Cancer Research. 78: 3846-3846 |
| Wong YN, Manola J, Hudes GR, et al. (2017) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clinical Genitourinary Cancer |
| Engle JA, Traynor AM, Campbell TC, et al. (2017) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155217704989 |
| Mahalingam D, Wilding G, Denmeade S, et al. (2016) Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. British Journal of Cancer. 114: 986-94 |
| Haas NB, Manola J, Uzzo RG, et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England) |
| Kyriakopoulos CE, Heath EI, Eickhoff JC, et al. (2016) A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Investigational New Drugs |
| Scher HI, Morris MJ, Stadler WM, et al. (2016) Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology |
| Yu J, Weichmann AM, Craig A, et al. (2016) Abstract 4968: “Moonlighting Functions” of glycolytic enzymes relate to human prostate cancer invasion Cancer Research. 76: 4968-4968 |
| Carles J, Davis I, Bono JSd, et al. (2016) Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) Annals of Oncology. 27 |